• Red White & Bloom Brands is a cannabis multi-state operator building on opportunities in Michigan, Florida, Illinois, California, Arizona, Oklahoma and Massachusetts to create a synergistic portfolio throughout North America
• RWB is also building its hemp-based CBD products retail throughout the United States and into international markets
• The company has released its third quarter financial report on revenue growth, operational development and progress in finalizing additional agreements
• The report notes revenues grew from $6.1 million to $11.8 million year-over-year, largely as the result of its acquisition of its premium Platinum Vape
• The company anticipated having 30 grow pods in place at its newly acquired manufacturing facility in Florida by Dec. 1, with expected revenue generation of $50.8 million during the facility’s first full year

Cannabis brand builder Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multi-state operator aiming to become one of the top three in the United States’ cannabis industry, is riding the popularity of its trademarked Platinum Vape to remarkable revenue growth, recording a 93 percent increase year-over-year in its just-released third quarter financial report. The financial results note that the majority of the company’s revenue comes from sales of cannabis finished products through third party wholesaling to retailers, delivering quarterly revenues of $11.8 million and EBITDA of $5.9 million that reverses an EBITDA loss of $5.8 million in Q3 2020 for a gain of $11.9 million. “In the third quarter, we made excellent progress in laying additional building blocks in our core operating states of Florida, Michigan, and California to become more vertically integrated where it will be most profitable,” Red White & Bloom Chairman and CEO Brad Rogers stated in announcing the results (https://ibn.fm/7ZIwi). “This will help drive increased revenue and margins for the company.” Platinum Vape was named the No. 1 brand for vape cartridges in Michigan by analysts at The Arcview Group & Headset in conjunction with Greentank vape manufacturing, according to the report. In California, Red White & Bloom transitioned management oversight of Platinum Vape brand to its own team after acquiring the brand during the third quarter, while in Michigan where the company uses a third-party manufacturer for Platinum Vape sales RWB took over operational control. RWB hosted a conference call about the earnings report with investors on Nov. 30. A recording of the call was placed on RWB’s Investor Relations website at https://ibn.fm/HMISm and a replay of the call is also available for 90 days by dialing 877-660-6853 or 201-612-7415 then entering access ID:13725118. The company is mostly focused on cannabis industry development within the largest U.S. markets for it, namely Florida, Michigan, Illinois, Massachusetts, Arizona and California. For its hemp-based CBD products, RWB expects the scope of its operations to take in foreign markets as well as the United States. In Florida, RWB has been transitioning 30 grow pods to its recently acquired 45,000-square-foot greenhouse in Orange County, with expectations that the grow pods would be fully planted by Dec. 1 and capable of producing $50.8 million in revenue during its first full year. “We will update shareholders on our progress shortly and are eager to share how our work in Florida and other areas is coming to fruition in Q1 2022 quarterly results,” Rogers stated. Among other developments shared in the third quarter report, RWB noted that it anticipates leveraging cost sharing and other economies of scale to further improve its profit margin once it closes the pending acquisition of a Michigan investee, which will allow the company to be vertically integrated. “RWB is being very strategic in pursuing vertical integration only when there is value to be added. We aim to be asset light and brand rich,” CFO Chris Ecken stated. “Our strategy is to support the brands in the most profitable way. We have been putting the teams in place to support this strategy in each state where we operate.” For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

To great acclaim, the National Cannabis Industry Association (“NCIA”) held its 7th Annual Cannabis Business Summit & Expo at San Francisco’s Moscone Center on December 15-17, 2021. As the oldest and largest trade association representing legal cannabis businesses, NCIA gathered together more than 125 expert speakers in over 80 educational sessions, as well as hundreds of exhibitors from across the cannabis ecosystem, for the industry’s most influential B2B event and trade show. Attendees from across the country were welcomed by San Francisco Mayor, London Breed. Her opening address honored the 30th anniversary of the Proposition P ballot initiative, which was instrumental in legalizing the use of medical cannabis in San Francisco. “I’m thrilled to see the industry return to San Francisco, where the movement for medicinal cannabis use began,” stated Mayor Breed. “I’d like to thank NCIA for welcoming me to the stage and for hosting their annual Summit here in San Francisco. Their events help advance our industry in a myriad of ways across social equity, policy, and other important issues while helping connect industry leaders from across the globe.” As part of its speaker line-up, NCIA’s 7th Annual Cannabis Business Summit & Expo presented two high-profile keynote sessions focusing on the future of cannabis and essential issues. The first session featured Troy Datcher, CEO of The Parent Company. In conversation with Adrian Farquharson, founder of MARY Magazine, Datcher shared his personal stories while enlightening attendees on his work to make an impact within the sector. The second keynote showcased a round-table discussion with entrepreneur Jim McAlpine moderating elite athletes Calvin Johnson Jr., Rachael Rapinoe, Anna Symonds, and Marvin Washington. As former members of the NFL, NCAA, European Professional Soccer League, and Women’s Premier League Rugby, the group provided insights into the headline-making question, “What is the role of cannabis in professional sports?” This year’s event also marked the debut of BLOOM: A Cannabis Brands Experience, showcasing a uniquely immersive sensory exploration. For the first time at Cannabis Business Summit & Expo, attendees were able to see, touch, and smell products from a national selection of cannabis brands specializing in flower, pre-roll, oil, edibles, and more. BLOOM allowed licensed retailers and infused product manufacturers to discover some of the most exciting cannabis brands currently on the rise. Looking back on this highly-anticipated, successful event, Aaron Smith, Co-Founder, and CEO of NCIA, provided the following comments: “In a word: amazing. I am truly amazed at the show of support from cannabis leaders from across the country over the last three days,” said Smith. “Attendance exceeded expectations, and never have we hosted such an esteemed group of speakers and exhibitors on the leading edge of this booming sector.” For more information on NCIA and upcoming events, visit the following website: https://cannabisbusinesssummit.com.

• Global crisis accelerated adoption of analytics and AI; momentum will continue into the 2020s.
• An estimated 86% of survey respondents say that AI is becoming a “mainstream technology.”
• Pluaris generates an annotated data feed based on specified topics of interest.

Accelerated by the global pandemic, the adoption of artificial intelligence (“AI”) is gaining steam, with 2022 projected to be a year when AI becomes a “mainstream technology” (https://ibn.fm/ulgS4). Nowigence Inc. (NOWG), a fast-growing SaaS (Software-as-a-Service) company that has developed an innovative, ready-to-use artificial intelligence (“AI”) platform called Pluaris(TM), is establishing a stronghold in the burgeoning AI space. “When it comes to digital transformation, the Covid crisis has provided important lessons for business leaders,” reported a recent Harvard Business Review article. “Among the most compelling lessons is the potential data analytics and artificial intelligence brings to the table. “The crisis accelerated the adoption of analytics and AI, and this momentum will continue into the 2020s, surveys show,” the article continued. “Fifty-two percent of companies accelerated their AI adoption plans because of the Covid crisis, a study by PwC finds. Just about all, 86%, say that AI is becoming a ‘mainstream technology’ at their company in 2021. . . . Will companies be able to keep up this heightened pace of digital and data-driven innovation as the world emerges from Covid? In the wake of the crisis, close to three-quarters of business leaders (72%) feel positive about the role that AI will play in the future, a survey by the AI Journal finds. Most executives (74%) not only anticipate AI will deliver more efficient make business processes but also help to create new business models (55%) and enable the creation of new products and services (54%).” Nowigence’s Pluaris is a cloud-based app created for just this time and place, enabling users to read more in less time. The innovative platform allows individuals, teams and enterprises to quickly evaluate and analyze knowledge from massive amounts of public and private textual data (https://ibn.fm/k5rLl). A personal knowledge management tool, Pluaris generates an annotated data feed based on specified topics of interest and then automatically creates a permanent personal knowledge base from a user’s feed and private uploads. The app has human-like capabilities for comprehending textual data, providing concise summaries and precise answers to questions while also analyzing different data perspectives, discovering new connections, creating organized nested notes and allowing teams to work together by sharing in real time from anywhere in the world. Nowigence is focused on simplifying the challenges of learning. By integrating state-of-the-art data-processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://ibn.fm/NOW

• The AI-driven drug discovery program uses not only artificial intelligence but also machine learning, which is a relatively new concept and is continuously expanding
• The use of artificial intelligence in the drug development space may help eliminate or reduce the manual operations that a company typically must undergo to identify and make necessary improvements to drugs
• The new model will allow the company to rapidly screen billions of structures promoting near term patent filings for novel psychedelic molecules
• Mydecine has already been able to eliminate unsuccessful candidates early on with the use of this technology
• Mydecine’s primary focus is the compound psilocybin, which interacts with serotonin receptors in the human body, creating a psychedelic effect
• The company is currently working on four lead candidates which may be useful in the treatment of PTSD, smoking cessation, and substance abuse

A biotech and digital technology company aiming to transform the treatment of mental health and addiction disorders, Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) announced that it has completed a target-based model of the classic psychedelic serotonin receptor 5-HT2A for use in its artificial intelligence (“AI”)-driven drug discovery program. Through this new model, the company will be able to expedite the screening of billions of structures to determine which of the novel compounds will increase binding affinity and enable the continued creation of improved second and third-generation psychedelic molecules for medicinal use. By using artificial intelligence and machine learning (“ML”), the company has positioned itself to discover drug enhancements through more cost-effective means, and in turn, more effectively than the competition. The use of AI in the drug development space is relatively new, and the efforts are continuously expanding. The technology’s goal is to eliminate, or at least drastically reduce, the manual operations companies typically undergo to identify and make the necessary improvements to these drugs. Through the AI-driven drug discovery program, Mydecine is eliminating those drug candidates that are likely to fail early on in the development process. Without the use of AI or ML, companies have hypothesized which structures are likely to bind to the receptor and then manually synthesize each molecule and test each one individually, determining the likelihood of a successful binding agent. Manual processes like this can take up enormous amounts of time and money, which is why the use of AI technology to quickly expedite the elimination process of candidates is not only valuable but promising. “AI gives us an incredibly robust tool for screening potential novel psychedelic compounds. This screening gives us increased confidence in investing in the later stages of our drug development and enables rapid development in our pipeline,” Chief Science Officer Rob Roscow said, according to a company press release (https://ibn.fm/cSJAM). The primary focus of Mydecine has been the compound psilocybin. When ingested, psilocybin’s active metabolite psilocin interacts with the body’s serotonin receptor and triggers a psychedelic experience. It has been shown to trigger neuroplasticity, which is the brain’s way of reorganizing, a key feature in psychedelic-assisted-psychotherapies. The 5-HT2A receptor model is only the tip of the iceberg for Mydecine’s planned modeling, which will help to continue enhancing the AI-driven drug discovery program. The company has also filed a recent patent application around MYCO-004, which directly addresses precision in delivery control and shelf stabilization through dermal administration. Mydecine uses molecules found in nature as the necessary building blocks to create improved second-generation drugs. The company’s portfolio of new drugs represents major improvements to existing natural and synthetic compounds, including enhancing safety, efficacy, stability, dosing, and reducing side effects. There are currently four leading drug candidates, which include enhancements such as improved controllability and delivery mechanisms, enhanced stability and safety, and longer shelf-life. Clinical and preclinical stage trials are currently being conducted with Mydecine’s portfolio as potential treatments for PTSD, smoking cessation, and substance abuse. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Congressman Earl Blumenauer recently wrote to his peers, urging them to petition the DEA to permit terminally ill patients to use psilocybin as part of their treatment
• Although 41 states permit terminal patients to try investigational drugs, psilocybin continues to be banned by the DEA
• Change seems to be coming within the sector as evidenced by its decriminalization in cities such as Denver and Oakland
• Delic Corp has positioned itself as a leading psychedelic wellness platform, with business interests in ketamine infusion clinics, media, event management, and psilocybin research

In mid-December, Representative Earl Blumenauer circulated an open letter to his colleagues in Congress, urging them to join him in petitioning the DEA to permit patients suffering from terminal illnesses to use psilocybin as part of their treatment, without fear of being federally prosecuted (https://ibn.fm/1NxQf). Although 41 U.S. states as well as Congress have adopted right-to-try laws, which permits patients with terminal illnesses to try investigational drugs that are yet to receive approval, the DEA has remained steadfast in its stance to continue denying patients access to psilocybin. Nonetheless, the tide seems to be shifting. Scientific research within the psychedelics sector has increasingly uncovered the substance’s potential to relieve a broad array of psychological maladies, including depression, anxiety, and addiction. Delic Holdings (CSE: DELC) (OTCQB: DELCF) has sought to capitalize on the ongoing transformation within the sector, positioning itself as the nation’s leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. According to the National Institute of Mental Health, over 17 million Americans have at least one major depressive episode every year, and up to 30% of them receive insufficient help from current medical treatments. Meanwhile, a further estimated 40 million adults struggle with anxiety disorders. Within his letter, Blumenauer stated that there was a growing body of evidence which pointed towards the effectiveness and safety of psilocybin-assisted therapy as a possible way to provide care for patients with anxiety and/or treatment-resistant depression. He further explained that despite these promising findings, the pace of regulatory approval had been slow for a substance that occurred naturally, and which had evidence of its safe therapeutic use by humans for millennia. Representative Blumenauer’s missive and findings seek to accelerate a process that has already begun to be reflected in policy adjustments within certain sectors of the government. In a move towards addressing the growing health crisis in 2018, the FDA moved towards granting psilocybin “breakthrough therapy” status for the treatment of severe depression. Shortly thereafter, Denver and then later Oakland voted to decriminalize the use of psilocybin mushrooms, with the state of California currently reviewing a bill to decriminalize a wide variety of psychedelics (https://ibn.fm/X2kao). Founded in 2018, Delic Corp has sought to transform itself into a champion of the psychedelic wellness sector, including psilocybin, through its myriad business interests. The company’s operations now include the largest chain of psychedelic wellness clinics with Ketamine Wellness Centers (“KWC”) and Ketamine Infusion Centers (“KIC”); trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; and Meet Delic, the world’s largest psychedelic wellness event. With the sector on the cusp of broad-based legalization, the psychedelic drugs market is now projected to grow to a size of $10.75 billion by 2027, up from $4.75 billion in 2020 with a forecast CAGR of 12.36 percent over the period of 2021-2027 (https://ibn.fm/LPnCo). With its business spanning all aspects of the sector, Delic Corp looks optimally positioned to benefit from the continued growth in adepts to the sector as well as ongoing legalization efforts which are increasingly making waves around the world. For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• Bitcoin saw many different milestones during 2021, including surpassing $1 trillion in market value
• LQwD launched its PaaS, lqwd.tech, on November 17, amidst the Adopting Bitcoin – A Lightning Summit in El Salvador
• The Lightning Network has seen explosive growth since January 2021
• LQwD’s corporate and operational update highlights several of the company’s achievements regarding funding, agreements to drive Bitcoin adoption and own Bitcoin deployment to procure additional Lightning Network nodes and provide liquidity for the platform

Bitcoin was officially launched 13 years ago on January 3, 2009, by Satoshi Nakamoto, the pseudonym used by the person or persons who created the cryptocurrency, wrote and published a dedicated white paper on the topic and deployed its initial implementation. As the world’s oldest cryptocurrency is celebrating its 13th anniversary, it does so after a period of significant achievement, with multiple major milestones and firsts attained in 2021 (https://ibn.fm/iOksX). These milestones include:

• Surpassing $1 trillion in market value – On February 19, 2021, bitcoin hit a $1 trillion market value for the first time
• Becoming the legal tender of El Salvador – The state’s authorities passed a new law to that effect in June 2021
• Launch of the first U.S. futures-based bitcoin ETF – In October, the ProShares futures-based bitcoin ETF made its market debut on the NYSE under the ticker “BITO”
• Bitcoin pricing hitting an all-time high – In November, the price of bitcoin achieved a new record, reaching over $69,044, according to CoinGecko
• 90% of the total bitcoin supply having been mined – As of December 2021, 90% of the total bitcoin supply has been mined, but the remainder of the coin is not expected to be mined until February 2140
• First bitcoin upgrade in four years – The first upgrade to bitcoin since 2017 happened in November 2021 and was named Taproot

Leveraging the growing popularity of cryptocurrency is LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a fintech company focused on creating enterprise-grade infrastructure to drive bitcoin adoption by enabling easier user access to the Lightning Network. The company released a dedicated platform as a service (“PaaS”) for the Lightning Network, https://lqwd.tech, in November. The platform is designed to make Lightning Network access simpler and to support more users looking to complete transactions instantly, securely, and inexpensively worldwide. Businesses connected can easily deploy, monitor, and manage LQwD’s Lightning Network nodes with little to no technical knowledge required. The company has deployed a part of its own Bitcoin holdings to procure additional nodes and provide liquidity for the platform. LQwD recently released its corporate and operational highlights, covering the non-brokered private placement for proceeds of C$5,000,000 (US$3.9 million) on June 9 and the completion of an offering of 23,000,000 units for proceeds of C$8,050,000 (US$ 6.3 million) on October 28. The company cumulatively acquired over C$9,000,000 worth of Bitcoin as an operating asset, increasing its holdings to approximately 150 Bitcoin. In addition to the financials, LQwD also entered a strategic services agreement with Netcoins, Inc., a subsidiary of BIGG Digital Assets Inc., and with Israeli-based Breez Development Ltd. The company also appointed Lightning Network experts Joost Jager and Roy Sheinfeld as strategic advisors and Alexandra Moxin as VP of Product. LQwD was also invited to participate in Adopting Bitcoin – A Lightning Summit in El Salvador. The summit took place November 16-18 and brought together key groups of industry experts in the Bitcoin and Lightning Network community, discussing the future of money and payments in Central American republic, as well as abroad (https://ibn.fm/VljMb). LQwD believes that the Lightning Network will become the monetary exchange network of the future, having already experienced impressive growth of more than 200% within the last 12 months and being anticipated to reach 700 million users by 2030. Other milestones achieved by the Network include:

• Node growth of 105% from 770 to over 15,000 nodes that have been established
• Bitcoin capacity increased from 1,125 BTC to almost 3,000 BTC (up 160%)
• From 38,000 to more than 73,000 payment channels established (up 92%)

Several entities have openly expressed their enthusiasm for incorporating the Lightning Network into their platforms, including Lightning Labs, Twitter, and Jack Dorsey’s Square. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Bitcoin prices rose to an all-time high of $69K in 2021, spurring a tide of consumer interest in the cryptocurrency market
• BlockFi capitalized on this demand through the release of the first-ever crypto rewards credit card, signing up 75,000 clients in 2021
• Improvements to its trading experience helped BlockFi expand its overall client base from 100,000 to 600,000 over the past 12 months

BlockFi, a financial services company dedicated to building a bridge between cryptocurrencies and traditional financial and wealth management products, recently released a letter from its founders providing an introspective on the company’s 2021 milestones and highlighting the crypto market’s continuous path of growth. Followers of crypto were treated to a wild ride in 2021. Bitcoin started the year under $30K before skyrocketing to an all-time high of $69K. The flagship of the cryptocurrency market ended the year around $47K, but this fluctuation has done little to quell the rising tide of interest in the evolving space. Flori Marquez, Co-Founder of BlockFi, noted in a mid-December interview with Yahoo! Finance that her firm has “seen huge moves in terms of American consumers being interested in [crypto].” In highlighting this growth in mainstream demand, she added:

• 1 in 10 people planned to gift crypto during 2021
• About 2/3 of Americans prefer to talk about crypto – five years ago, only 1% of people had ever traded crypto and 50% of Americans had never heard of crypto

Marquez went on to assert that crypto has become “more digestible” for the average consumer over the past five years, claiming that sustained upward price action and improved regulatory clarity will help foment a FOMO attitude toward crypto adoption in 2022. This outlook is promising for BlockFi. In 2021, the financial services pioneer grew its client base from 100,000 to over 600,000, introducing a number of exciting solutions along the way, including:

• The first-ever crypto rewards credit card, which has already paid out over $15 million in rewards to over 75,000 clients
• An improved trading experience featuring five new asset classes and instant ACH trading
• BlockFi Prime, an integrated platform where institutional investors can easily access, trade and borrow digital assets

“We are very excited to see that we’ve hit 75,000 people using the Bitcoin rewards credit card,” Marquez said in the December interview. “That’s absolutely huge, because most fintech companies look to see about 10,000 credit cards in their first year. So, the fact that we’re at 75K just really shows that Americans are banging down the door to earn different types of awards.” Looking ahead, BlockFi has announced plans to add trading capabilities for additional assets to its platform as it continues to find innovative ways to give its clients simple access to the returns available in the evolving crypto space. As Founders Flori Marquez & Zac Prince declared in a year-end summary, BlockFi is “heading into this year stronger than ever.” For more information, visit the company’s website at www.BlockFi.com

• StraightUp has hired experienced commodities entrepreneur and economic geologist Rod Husband as its new CEO as it enters 2022 in an expansionist phase
• Mineral property exploration company StraightUp Resources is building excitement for several properties it has optioned in the gold-producing region of Ontario’s famed Red Lake Mining District
• StraightUp also acquired a mine in the historic Bullfrog Boom area surrounding Beatty, Nevada during recent months
• The company recently added a listing on the OTCQB Venture Market and eligibility for electronic clearing and settlement of its transactions through the Depository Trust Company
• The company has completed heliborne investigations at three of its five Ontario sites, and has confirmed multiple areas of high merit and potential mineralization on one that has previously been unexplored

Going into 2022, precious metals explorer StraightUp Resources (CSE: ST) (OTCQB: STUPF) is welcoming the leadership of new CEO Rod Husband, an accomplished entrepreneur and economic geologist with over 30 years of experience in the international commodity and finance sectors. StraightUp executive Mark Brezer will focus on his duties as president and director during a period of company growth and expansion into international markets. “This appointment strengthens management and brings a new layer of expertise to the team,” the company’s Dec. 16 announcement states (https://ibn.fm/ExibB). StraightUp Resources built its exploration and acquisition opportunities during 2021 by expanding on property options located in the gold-prolific greenbelt zones of Ontario’s Red Lake Mining district to add ownership of the West Cat gold and silver mine in the historically productive Bullfrog Boom district surrounding Beatty, Nevada in the United States. The company also announced the potential acquisition of the Mallay silver mine and processing plant in the Lima region, Peru through a right of exclusivity agreement (“ROE”) for all outstanding shares in Premier Silver Corp. that was set to expire at the end of December if not fulfilled. StraightUp’s pursuit of worthwhile economic, precious and base metal properties in North and South America has been most concentrated on the five Ontario projects that together comprise more than 21,087 hectares (52,107 acres). High-resolution heli-borne magnetic surveys (“MAGs”) were completed on three of them — Ferdinand, RLX North and RLX South, which together make up all but about 17,000 hectares of the exploration area. The company has advanced ground investigation in the Ferdinand project, which has confirmed several areas of potential mineralization the company is interested in. “This study represents a transformation of the Ferdinand Gold Project and we couldn’t be more excited about the road ahead in this unexplored and unappreciated section of the infamous Uchi subprovince,” Brezer stated when the results were announced in late November (https://ibn.fm/RvJhq). “We now have confirmation of D2 folding and ultramafic rocks, together considered to be a primary control for high-grade gold mineralization in this region, especially the Great Bear Resources Dixie Lake Gold Project,” he added. Great Bear Resources’ Dixie Lake project is a neighbor immediately to the west of the Ferdinand Gold Project, and made news in early December when mining company Kinross Gold Corporation announced an acquisition bid for Great Bear at a price of about $1.45 billion despite the lack of a maiden resource estimate by the company — an apparent indication Kinross thinks it could be a top-tier deposit area (https://ibn.fm/SRQ6q). The Ferdinand project has not yet had a registered drill hole because access is limited to logging roads, but forestry logging operations are expected to expand on the property and the property is only 13 km northwest of the town of Slate Falls and larger roadways. Its unexplored status within one of the best metal-endowed greenstone belts in the world makes it a particularly exciting prospect for the coming year. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

• CEO to participate in panel discussion, fireside chat focusing on psychedelics
• The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape
• CYBN is implementing a three-pillar strategy

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin CEO’s upcoming participation in two virtual investor conferences (https://ibn.fm/1zAF4). The company announced that CEO Doug Drysdale has been invited to participate in a panel discussion titled “Psychedelics: More Than Just a Trip” during the 11th annual LifeSci Partners Corporate Access Event. The two-day event is slated for Jan. 5–7, 2022, with the panel discussion scheduled for Wednesday, Jan. 5, at 10 a.m. EST. (Click here to register and access the webcast.) In addition, Drysdale will participate in a fireside chat during the virtual three-day H.C. Wainwright Bioconnect Conference. Drysdale’s fireside chat will be available on demand beginning Jan. 10, 2022, at 7 a.m. EST. (Click here to register and access the webcast.) Drysdale’s expertise in the psychedelics field is being recognized as Cybin continues to establish itself as a leading ethical biopharmaceutical company. The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape. To accomplish this lofty vision, Cybin is following a three-pillar strategy based on the following: novel drug-discovery platform (API modification), proprietary drug-delivery systems (R&D) and innovative treatment regimens (https://ibn.fm/vMkCy). Cybin is developing new APIs through selective modifications of tryptamine and phenethylamine-based scaffolds specifically to alter their pharmacokinetics without modifying their therapeutic potential. These modifications involve replacing selective hydrogens with deuterium atoms. The company’s R&D, categorized under the proprietary drug-delivery systems, involves the development of an efficient delivery system that attempts to bypass liver metabolism with a direct path to the brain, thereby providing faster onset. The company is also looking to identify modified-release formulations with the potential to reduce side effects and control exposure, as well as providing dose control through its proprietary device platform. Cybin’s treatment regimen is where science meets technology. Its exclusive EMBARK is a best-practices psychotherapy program designed to provide consistent therapist training and consistent psychotherapy delivery in clinical trials. Cybin is a leading ethical biopharmaceutical company and is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for patients to address a multitude of mental health issues. The company operates in the United States, the United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Lexaria has received approval from the Independent Review Board for its DehydraTECH-CBD Human Clinical HYPER-H21-4 study
• The approval signals the company has taken the appropriate steps to protect the rights and welfare of human subjects participating in its fourth human study
• HYPER-H21-4 should “de-risk” outcomes prior to Lexaria’s planned entry into regulatory pathways for the use of DehydraTECH-CBD to treat hypertension and perhaps other forms of cardiovascular disease
• Previous studies – HYPER-H21-1 and HYPER-H21-2 – have evidenced a remarkable, rapid, and safe drop in blood pressure with DehydraTECH-CBD

A little less than two months after Lexaria Bioscience (NASDAQ: LEXX) announced it was readying the study protocols for HYPER-H21-4, its most ambitious and comprehensive study yet, for submission to the Independent Review Board (“IRB”) with approval anticipated by January 2022 (https://ibn.fm/DASCc), the company is celebrating the receipt of the approval ahead of schedule. An administrative body created to safeguard the rights and welfare of human subjects recruited to participate in research activities, the IRB is tasked with approving, disapproving, monitoring, and requiring modifications to studies and their respective protocols (https://ibn.fm/IVBB0). The IRB approval signals Lexaria has taken the appropriate steps to protect the rights and welfare of human subjects participating in its HYPER-H21-4 study, Lexaria’s fourth human clinical study evaluating DehydraTECH-CBD as a potential treatment for hypertension and perhaps other forms of cardiovascular disease.  In total, the study is expected to comprise 60 volunteers aged between 45 and 70 years (https://ibn.fm/Y9p0I). As part of the research, which will utilize a double-blinded, randomized cross-over design, and placebo control, a subset of the volunteers will already be using the leading standard of care hypertension drugs such as ACE inhibitors with or without diuretics. The rest will use three 150 mg doses of DehydraTECH-CBD daily for six weeks, the duration of the study. Dosing is tentatively set to begin by April 2022. Results from study HYPER-H21-4 are expected to add to Lexaria’s growing body of evidence for the effectiveness of DehydraTECH-CBD against hypertension.  In addition, it will explore the potential for longer term health benefits that might otherwise remain undetected, with the 6-week duration of the study enabling the company to gather critical data monitoring of DehydraTECH-CBD over time. HYPER-H21-4 will involve multiple types of analysis, including 24-hour ambulatory blood pressure (the primary outcome); arterial stiffness and autonomic balance; brain structure and function through brain MRI; blood markers; renal, hepatic, sleep quality/daytime sleepiness/sleep disorders; actigraphy, geriatric depression scale, perceived stress, and back anxiety inventory. The enormous volumes of data from the study, if positive, should support the company’s plans to enter regulatory pathways expected to eventually result in regulatory approval to use DehydraTECH-CBD as a treatment for hypertension and possibly other types of cardiovascular disease. Already, Lexaria’s previous human studies, HYPER-H21-1 and HYPER-H21-2, have evidenced a remarkably rapid, and safe drop in blood pressure with DehydraTECH-CBD. Furthermore, according to an announcement issued last month, the HYPER-H21-3, also regarded as a ‘stress test’ study, was conducted to examine DehydraTECH-CBD’s effects on pulmonary vascular function in normotensive individuals exposed to hypoxia (oxygen tension). This third study will fill a knowledge gap that existed as regards the extent to which CBD may act as a novel treatment for hypoxic pulmonary vasoconstriction (“HPV”) and as a potential alternative treatment for pulmonary hypertension. Currently valued at an estimated $28 billion, the antihypertensive drug market is expected to continue growing (https://ibn.fm/W39lb). However, with less than 25% of persons with hypertension having successfully controlled their condition using medication, Lexaria notes the potential market for hypertension drugs would be much greater than the estimated figure if an affordable drug with few or no side effects were available. “Lexaria believes that its DehydraTECH-CBD may introduce a more tolerable antihypertensive treatment option that may be used alone or in combination with other medications, to reduce BP with fewer discouraging and unwanted side effects,” reads the December 29 news release reporting the receipt of the IRB approval. A global leader in enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs, Lexaria has developed DehydraTECH, a patented technology that improves the bioavailability of pharmaceuticals and therapeutics. The technology combines active pharmaceutical ingredients (“API”), such as cannabidiol (“CBD”), with the product achieving fast onset, increased bioavailability, and improved effectiveness, according to subjective and objective clinical testing. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX